chronic diseases, today celebrated its listing on NYSE Euronext in Paris.
Founded in 2005, ADOCIA designed and developed BioChaperone®, a proprietary technology platform that improves the therapeutic performance of proteins such as insulin and the growth factors used to treat diabetes and chronic wounds. The company has several promising products in its portfolio and is currently working in two development partnerships with pharmaceutical companies that rank among the very largest in the industry. It recently signed an exclusive worldwide license with a major company to develop an ultra-fast-acting insulin analogue, an agreement that involves milestone payments that could total as much as $166 million. ADOCIA is based in Lyon and has 49 employees, with 80% working in Research & Development.
ADOCIA (ticker code: ADOC) was listed through the admission to trading of 4,458,710 existing shares and 1,592,798 new shares issued under a Global Offering, including full exercise of the extension clause. The Global Offering raised a total of €25.3 million, which could rise to €29.1 million if the Over-allotment option is fully exercised.
The admission and issue price of ADOCIA shares was set at €15.88. Market capitalisation stood at around €96.1 million on the day of listing.
“We are delighted to welcome Lyon-based ADOCIA to NYSE Euronext in Paris. Lyon and its region are home to many chemical, pharmaceutical and biotechnology companies. Together they form a vibrant hub that is France’s premier market for life sciences and one of the largest in Europe,” said Marc Lefèvre, Head of European Coverage at NYSE Euronext.
“The stock exchange contributes to regional job creation, and there is no doubt that in recent years it has strengthened Lyon’s emergence as the second large employment hub in France,” he added. “I would like to congratulate ADOCIA on its successful public offering and also extend my warmest thanks to our local partners, with whom we have set up agreements and who help to offer businesses, particularly SMEs, the benefits of strong momentum for financial markets.”
Gérard Soula, CEO and cofounder of ADOCIA, said: “We are very pleased and proud to be the first company to finalise arrangements for funding this year through a listing on NYSE Euronext in Paris –and to do so successfully. On behalf of ADOCIA, I would like to thank all the shareholders who have put their trust in us and who will henceforth accompany us in our growth. I would also like to wholeheartedly thank all our partners and our staff who have enabled us to successfully reach this major milestone. On the eve of this new phase in our development, we would like to reaffirm our strategic intention of making ADOCIA a leading international company in the domains of regenerative medicine and the treatment of diabetes, a strategy made possible by the support of all our new and historical shareholders.”
Tel.: +33(0)1 49 27 10 82
NewCap. – Financial communications and investor relations
Axelle Vuillermet /Emmanuel Huuynh
Tel.: +33(0)1 44 71 94 94
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets — the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca — represent one-third of the worlds equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit: www.nyx.com.
A Biotech company founded by Gérard, Olivier and Rémi Soula (Gérard Soula is the founder of Flamel Technologies) in 2005, ADOCIA’s mission is to create best-in-class drugs for the mass market from the innovative formulation of certain already-approved therapeutic proteins.
To date, ADOCIA has already carried out two collaborative development programs with Pharma majors. Furthermore, ADOCIA recently signed an exclusive worldwide license contract with Eli Lilly for the development of an ultra-fast insulin analog.
As well as the SOULA family, which is ADOCIA’s main shareholder with close to 26% of the Company’s capital, ADOCIA’s shareholders include some of the largest investment funds specializing in innovation: Innobio and Bioam (managed by CDC Entreprises), IdInvest, Amundi, Viveris, Oréo Finance and SHAM.
For further information about ADOCIA, go to www.adocia.com.
 The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.